May. 15 at 11:07 PM
$TRT $POET $AAOI $AEHR
I will repost this again for newcomers
TRT: The most undervalued stock in the AI market right now.
POTENTIAL CONSERVATIVE UPSIDE:
10x sales = roughly
$490M valuation/46$
15x sales = roughly
$740M valuation/74$
20x sales = roughly
$980M valuation/98$
(In comparing to AEHR which currently trades at 63x sales)
VALUATION EXPLANATION:
Recent highlights from Trio-Tech International latest Q3 FY2026 report are actually very impressive for a company trading at only around 2-2.5x sales:
* Revenue grew 124% YoY in Q3 FY2026 driven by strong semiconductor reliability testing demand tied to AI compute and automotive chips.
* Previous quarter already showed 82% YoY growth, meaning this is now multiple consecutive hypergrowth quarters.
* Semiconductor Back-End Solutions segment has been the main growth engine, benefiting from AI GPU and EV chip testing demand.
* TRT secured meaningful AI GPU burn-in board orders, including a reported
$5.3M AI GPU platform order.
* Company expanded production capacity in Malaysia to support growing demand.
* TRT remains profitable or near breakeven while scaling, unlike many speculative microcaps.
* TRT also strengthened its balance sheet with a ~
$10M raise for expansion rather than survival financing.
That valuation disconnect is why many TRT bulls believe the stock is severely undervalued relative to AEHR.
If TRT were valued at AEHR’s current ~63x sales multiple:
49.2M x 63 :
That would imply roughly a
$3.1 billion valuation for TRT.
That suggests TRT would theoretically need to rise about 25x just to trade at AEHR’s current sales multiple.
Now realistically, the market probably won’t give TRT a 63x sales multiple because:
* TRT is much smaller and less institutionally followed
* Gross margins are lower than AEHR
* TRT trades on NYSE American microcap territory
* Liquidity and float are much smaller
* AEHR has historically received premium “pure play AI/silicon carbide” sentiment
But even assigning TRT a more conservative multiple:
* 10x sales = roughly
$490M valuation/46$
* 15x sales = roughly
$740M valuation/74$
* 20x sales = roughly
$980M valuation/98$
(Based on 10 million share count, 6 million float)
All still substantially above current levels if growth continues.
The key thing the market will watch now is whether TRT can:
1. Sustain AI-related order momentum
2. Improve margins while scaling
3. Continue sequential growth
4. Convert AI GPU testing demand into long-term recurring revenue
If they execute, the valuation gap versus AEHR becomes harder for the market to ignore.
